Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Yemarshet K GebreyohannesAgnieszka WozniakMadalina-Elena ZhaiJasmien WellensJasmien CornillieUlla VanleeuwErica EvansAlexandra K GardinoChristoph LengauerMaria Debiec-RychterRaf M E SciotPatrick SchöffskiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Avapritinib has significant antitumor activity in GIST PDX models characterized by different KIT mutations and sensitivity to established TKI. These data provide strong support for the ongoing clinical trials with avapritinib in patients with GIST (NCT02508532, NCT03465722).